<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503332</url>
  </required_header>
  <id_info>
    <org_study_id>POT-CP121614</org_study_id>
    <nct_id>NCT02503332</nct_id>
  </id_info>
  <brief_title>Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy</brief_title>
  <acronym>FILLY</acronym>
  <official_title>A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients With Geographic Atrophy (GA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apellis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apellis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the study are to assess the safety, tolerability and evidence of&#xD;
      activity of multiple intravitreal (IVT) injections of pegcetacoplan in subjects with&#xD;
      Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, prospective, multicenter, randomized, single-masked, sham-controlled&#xD;
      study to assess the safety, tolerability and evidence of activity of multiple IVT injections&#xD;
      of pegcetacoplan in subjects with GA secondary to Age-Related Macular Degeneration.&#xD;
&#xD;
      The study will randomize approximately 240 subjects to obtain at least 200 evaluable subjects&#xD;
      across 40 multinational sites.&#xD;
&#xD;
      Subjects will be randomized in a 2:2:1:1 manner to receive pegcetacoplan Monthly (AM),&#xD;
      pegcetacoplan Every-Other-Month (AEOM), Sham injection Monthly (SM) or Sham injection&#xD;
      Every-Other-Month (SEOM), respectively.&#xD;
&#xD;
      All subjects will return to the clinical site on Day 7 to assess acute safety after the first&#xD;
      injection. After that, subjects in the monthly groups will return to the clinical site for&#xD;
      additional pegcetacoplan (or Sham) injections and study procedures every month until Month&#xD;
      12. Subjects in the Every-Other-Month groups will return to the clinical site for additional&#xD;
      pegcetacoplan (or Sham) injections and study procedures every two months until Month 12. All&#xD;
      subjects will return for follow-up visits on Months 15 and 18 (3 and 6 months after last&#xD;
      injection, respectively).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2015</start_date>
  <completion_date type="Actual">January 17, 2018</completion_date>
  <primary_completion_date type="Actual">July 14, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Least Square (LS) Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12</measure>
    <time_frame>Baseline (screening) and Month 12.</time_frame>
    <description>The square root GA lesion size (i.e. transformed area of GA) was measured by FAF photographs. Baseline was defined as the last available, non-missing observation prior to first study drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity</measure>
    <time_frame>From the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).</time_frame>
    <description>A TEAE was defined as any adverse event (AE) that commenced or worsened on or after time of first study drug administration up to 60 days beyond last dose of study drug. A treatment-related TEAE was defined as a TEAE with a relationship to study drug of possibly related or probably related or not reported. Severity of TEAEs were categorized as mild; moderate; severe; life-threatening or death related to TEAE, according to Common Terminology Criteria for AEs v4.03. A TEAE of special interest (TEAESI) was defined as a TEAE of scientific and medical concern specific to pegcetacoplan, whether serious or non-serious.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LS Mean Change From Baseline in Untransformed GA Lesion Size in the Study Eye at Month 12</measure>
    <time_frame>Baseline (Day 1) and Month 12.</time_frame>
    <description>The untransformed area of GA was measured by FAF. Baseline is defined as the last available, non-missing observation prior to first study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score of the Study Eye at Month 12</measure>
    <time_frame>Baseline (Day 1) and Month 12.</time_frame>
    <description>The BCVA letter score was determined using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. The score ranges from 0 to 100 letters, lower number indicating reduced visual acuity; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Change From Baseline in Low Luminance BCVA (LL-BCVA) Score in the Study Eye at Month 12</measure>
    <time_frame>Baseline (Day 1) and Month 12.</time_frame>
    <description>The LL-BCVA was measured by placing a 2.0-log-unit neutral density filter over the best correction and having the participant read the normally illuminated ETDRS chart. The score ranges from 0 to 100 letters, lower number indicating worse vision; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Change From Baseline in Low Luminance VA (LL-VA) Deficit Score in the Study Eye at Month 12</measure>
    <time_frame>Baseline (Day 1) and Month 12.</time_frame>
    <description>The LL-VA deficit score is calculated as BCVA score minus LL-BCVA score. The LL-VA deficit score ranges from 0 to 100 letters, lower number indicating worse deficit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Change From Baseline in Distance of GA Lesion From the Fovea (Foveal Encroachment) in the Study Eye at Month 12</measure>
    <time_frame>Baseline (Day 1) and Month 12.</time_frame>
    <description>The foveal encroachment in the study eye was measured by FAF. Baseline is defined as the last available, non-missing observation prior to first study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Macular Neovascularization (MNV) TEAEs in the Study Eye</measure>
    <time_frame>From the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).</time_frame>
    <description>The number of subjects with any MNV TEAEs in the study eye was identified via clinical review of all ocular TEAEs.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">246</enrollment>
  <condition>Geographic Atrophy</condition>
  <arm_group>
    <arm_group_label>Pegcetacoplan 15 mg/100 µL Monthly for 12 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every month for 12 consecutive months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegcetacoplan 15 mg/100 µL EOM for 12 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month (EOM) for 12 consecutive months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Monthly for 12 months</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects will receive a Sham procedure every month for 12 consecutive months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham EOM for 12 months</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects will receive a Sham procedure every other month (EOM) for 12 consecutive months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegcetacoplan</intervention_name>
    <arm_group_label>Pegcetacoplan 15 mg/100 µL EOM for 12 months</arm_group_label>
    <arm_group_label>Pegcetacoplan 15 mg/100 µL Monthly for 12 months</arm_group_label>
    <other_name>APL-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Procedure</intervention_name>
    <arm_group_label>Sham EOM for 12 months</arm_group_label>
    <arm_group_label>Sham Monthly for 12 months</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Unless specified otherwise, ocular specific inclusion criteria apply to&#xD;
        the study eye only.&#xD;
&#xD;
          1. Male or Female.&#xD;
&#xD;
          2. Age greater than or equal to 50 years.&#xD;
&#xD;
          3. BCVA of 20/320 (Snellen equivalent) or better using ETDRS charts.&#xD;
&#xD;
          4. Diagnosis of GA of the macula secondary to age-related macular degeneration, confirmed&#xD;
             within 14 days prior to randomization by the central reading center (CRC) using Fundus&#xD;
             Autofluorescence (FAF) images, as well as the following criteria:&#xD;
&#xD;
               1. Total GA area must be ≥ 2.5 and ≤ 17.5 mm2 (1 and 7 disk areas [DA]&#xD;
                  respectively), determined by screening images of FAF.&#xD;
&#xD;
               2. If GA is multifocal, at least one focal lesion must be ≥ 1.25 mm2 (0.5 DA).&#xD;
&#xD;
               3. GA can be completely visualized on the macula centered image.&#xD;
&#xD;
               4. GA must be able to be photographed in its entirety.&#xD;
&#xD;
               5. GA must be able to be measured separately from any areas of peripapillary atrophy&#xD;
                  as assessed by the CRC.&#xD;
&#xD;
               6. Presence of any pattern of hyperautofluorescence in the junctional zone of GA.&#xD;
                  Absence of hyperautoflouorescence (i.e. pattern = none) is exclusionary. See Holz&#xD;
                  et al. 2007.1&#xD;
&#xD;
          5. Female subjects must be:&#xD;
&#xD;
               1. Women of non-child-bearing potential (WONCBP), or&#xD;
&#xD;
               2. Women of child-bearing potential (WOCBP) with a negative pregnancy test at&#xD;
                  screening and must agree to use protocol defined methods of contraception for the&#xD;
                  duration of the study.&#xD;
&#xD;
          6. Males with female partners of child-bearing potential must agree to use protocol&#xD;
             defined methods of contraception and agree to refrain from donating sperm for the&#xD;
             duration of the study.&#xD;
&#xD;
          7. Willing and able to give informed consent.&#xD;
&#xD;
        Exclusion Criteria: Unless specified otherwise, ocular specific inclusion criteria apply to&#xD;
        the study eye only.&#xD;
&#xD;
          1. GA due to causes other than AMD such as Stargardt disease, cone rod dystrophy or toxic&#xD;
             maculopathies like plaquenil maculopathy.&#xD;
&#xD;
          2. Spherical equivalent of the refractive error demonstrating &gt; 6 diopters of myopia or&#xD;
             an axial length &gt;26 mm.&#xD;
&#xD;
          3. Any history or current evidence of exudative (&quot;wet&quot;) AMD including any evidence of&#xD;
             retinal pigment epithelium rips or evidence of neovascularization anywhere in the&#xD;
             retina based on fluorescein angiogram as assessed by the CRC.&#xD;
&#xD;
          4. Retinal disease other than AMD; however, benign conditions of the vitreous or&#xD;
             peripheral retina are not exclusionary (i.e. pavingstone degeneration).&#xD;
&#xD;
          5. Any ophthalmologic condition that reduces the clarity of the media and that, in the&#xD;
             opinion of the Investigator interferes with ophthalmologic examination (e.g. advanced&#xD;
             cataract or corneal abnormalities).&#xD;
&#xD;
          6. Any ophthalmologic condition that prevents adequate imaging of the retina judged by&#xD;
             the site or CRC.&#xD;
&#xD;
          7. Intraocular surgery (including lens replacement surgery) within 3 months prior to&#xD;
             randomization.&#xD;
&#xD;
          8. Aphakia or absence of the posterior capsule. Previous violation of the posterior&#xD;
             capsule is also excluded unless it occurred as a result of yttrium aluminum garnet&#xD;
             (YAG) laser posterior capsulotomy in association with prior posterior chamber&#xD;
             intraocular lens implantation and at least 60 days prior to Day 0.&#xD;
&#xD;
          9. Any ophthalmic condition that may require surgery during the study period.&#xD;
&#xD;
         10. Any contraindication to IVT injection including current ocular or periocular&#xD;
             infection.&#xD;
&#xD;
         11. History of uveitis or endophthalmitis.&#xD;
&#xD;
         12. History of IVT injection at any time.&#xD;
&#xD;
         13. Participation in another interventional clinical study, or use of any experimental&#xD;
             treatment for AMD or any other investigational new drug within 6 weeks or 5 half-lives&#xD;
             of the active (whichever is longer) prior to the start of study treatment. Note:&#xD;
             clinical trials solely involving observation, over-the-counter vitamins, supplements,&#xD;
             or diets are not exclusionary.&#xD;
&#xD;
         14. Medical or psychiatric conditions that, in the opinion of the investigator, make&#xD;
             consistent follow-up over the treatment period unlikely, or in general a poor medical&#xD;
             risk because of other systemic diseases or active uncontrolled infections.&#xD;
&#xD;
         15. Any screening laboratory value (hematology, serum chemistry or urinalysis) that in the&#xD;
             opinion of the Investigator is clinically significant and not suitable for study&#xD;
             participation.&#xD;
&#xD;
         16. Hypersensitivity to fluorescein.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Federico Grossi, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Apellis Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Speciality Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Asociates Mdical Goup</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Gavin Herbert Eye Institute/UC Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California - USC Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Byers Eye Institute at Stanford, Stanford School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Retina Associates</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Eye Microsurgical Institute, Inc.</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Health Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South East Retina</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Retina Associates</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Eye Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elman Research</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Retinal Consultants PC</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>45946</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Retinal Consultants, PC</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49586</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eyesight Opthalmic Services PA</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreous Retina Macula Consultants of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye Ear Nose and Throat Associates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University, Duke Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye Ear Nose and Throat Associates</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation/ Cole Eye Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Retina, PC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Research Institute of Texas</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Research Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute, PA</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>75803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Specialists</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston (The Woodlands)</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marsden Eye Specialists</name>
      <address>
        <city>Paramatta</city>
        <state>New South Wales</state>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Save Sight Institute, Sydney Eye Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Retina Clinic and Day Surgery</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney West Retina</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hobart eye Surgeons</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tasmanian Eye Institute</name>
      <address>
        <city>South Launceston</city>
        <state>Tasmania</state>
        <zip>7249</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victorian Eye and Ear Hospital</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Eye Research Australia</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lions Eye Institute</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Eye</name>
      <address>
        <city>Remuera</city>
        <state>Auckland</state>
        <zip>1050</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Eye Specialists</name>
      <address>
        <city>Merivale</city>
        <state>Christchurch</state>
        <zip>8014</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 14, 2015</study_first_submitted>
  <study_first_submitted_qc>July 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2015</study_first_posted>
  <results_first_submitted>August 4, 2020</results_first_submitted>
  <results_first_submitted_qc>September 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2020</results_first_posted>
  <disposition_first_submitted>November 13, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>November 13, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 19, 2019</disposition_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Geographic Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT02503332/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT02503332/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This Phase II, randomized, single-masked, sham injection-controlled study in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) was conducted at 47 sites (46 active) in 3 countries between 24 September 2015 and 14 July 2017 (Data cut-off date, Month 12).</recruitment_details>
      <pre_assignment_details>Subjects were randomized in a 2:2:1:1 manner to receive treatment with pegcetacoplan monthly, pegcetacoplan every-other-month (EOM), sham monthly or sham EOM, respectively. A total of 246 subjects were randomized in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pegcetacoplan Monthly</title>
          <description>Subjects received intravitreal (IVT) injections of pegcetacoplan 15 milligrams (mg)/100 microliters (μL) once monthly for 12 months.</description>
        </group>
        <group group_id="P2">
          <title>Pegcetacoplan EOM</title>
          <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.</description>
        </group>
        <group group_id="P3">
          <title>Sham Monthly</title>
          <description>Subjects received sham injections once monthly for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.</description>
        </group>
        <group group_id="P4">
          <title>Sham EOM</title>
          <description>Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor's Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Request</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intent to Treat (ITT) population included all randomized subjects who received at least one injection of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Pegcetacoplan Monthly</title>
          <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.</description>
        </group>
        <group group_id="B2">
          <title>Pegcetacoplan EOM</title>
          <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.</description>
        </group>
        <group group_id="B3">
          <title>Sham Pooled</title>
          <description>Sham Monthly: Subjects received sham injections once monthly for 12 months.&#xD;
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="81"/>
            <count group_id="B4" value="246"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.6" spread="7.51"/>
                    <measurement group_id="B2" value="81.0" spread="7.55"/>
                    <measurement group_id="B3" value="78.4" spread="7.43"/>
                    <measurement group_id="B4" value="79.7" spread="7.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="154"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GA Lesion Size (fundus autofluorescence [FAF]) in the Study Eye</title>
          <units>millimeter square (mm^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.0" spread="3.84"/>
                    <measurement group_id="B2" value="8.9" spread="4.47"/>
                    <measurement group_id="B3" value="8.2" spread="4.05"/>
                    <measurement group_id="B4" value="8.4" spread="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Least Square (LS) Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12</title>
        <description>The square root GA lesion size (i.e. transformed area of GA) was measured by FAF photographs. Baseline was defined as the last available, non-missing observation prior to first study drug administration.</description>
        <time_frame>Baseline (screening) and Month 12.</time_frame>
        <population>The modified ITT (mITT) population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Pegcetacoplan Monthly</title>
            <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Pegcetacoplan EOM</title>
            <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Sham Pooled</title>
            <description>Sham Monthly: Subjects received sham injections once monthly for 12 months.&#xD;
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Square (LS) Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12</title>
          <description>The square root GA lesion size (i.e. transformed area of GA) was measured by FAF photographs. Baseline was defined as the last available, non-missing observation prior to first study drug administration.</description>
          <population>The modified ITT (mITT) population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.025"/>
                    <measurement group_id="O2" value="0.28" spread="0.026"/>
                    <measurement group_id="O3" value="0.35" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity</title>
        <description>A TEAE was defined as any adverse event (AE) that commenced or worsened on or after time of first study drug administration up to 60 days beyond last dose of study drug. A treatment-related TEAE was defined as a TEAE with a relationship to study drug of possibly related or probably related or not reported. Severity of TEAEs were categorized as mild; moderate; severe; life-threatening or death related to TEAE, according to Common Terminology Criteria for AEs v4.03. A TEAE of special interest (TEAESI) was defined as a TEAE of scientific and medical concern specific to pegcetacoplan, whether serious or non-serious.</description>
        <time_frame>From the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).</time_frame>
        <population>The safety population included all randomized subjects who received at least one injection of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Pegcetacoplan Monthly</title>
            <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Pegcetacoplan EOM</title>
            <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Sham Pooled</title>
            <description>Sham Monthly: Subjects received sham injections once monthly for 12 months.&#xD;
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity</title>
          <description>A TEAE was defined as any adverse event (AE) that commenced or worsened on or after time of first study drug administration up to 60 days beyond last dose of study drug. A treatment-related TEAE was defined as a TEAE with a relationship to study drug of possibly related or probably related or not reported. Severity of TEAEs were categorized as mild; moderate; severe; life-threatening or death related to TEAE, according to Common Terminology Criteria for AEs v4.03. A TEAE of special interest (TEAESI) was defined as a TEAE of scientific and medical concern specific to pegcetacoplan, whether serious or non-serious.</description>
          <population>The safety population included all randomized subjects who received at least one injection of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs with mild intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs with moderate intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs with severe intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs with life-threatening intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death related to TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAESIs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to study/treatment discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Change From Baseline in Untransformed GA Lesion Size in the Study Eye at Month 12</title>
        <description>The untransformed area of GA was measured by FAF. Baseline is defined as the last available, non-missing observation prior to first study drug administration.</description>
        <time_frame>Baseline (Day 1) and Month 12.</time_frame>
        <population>The mITT population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Pegcetacoplan Monthly</title>
            <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Pegcetacoplan EOM</title>
            <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Sham Pooled</title>
            <description>Sham Monthly: Subjects received sham injections once monthly for 12 months.&#xD;
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Change From Baseline in Untransformed GA Lesion Size in the Study Eye at Month 12</title>
          <description>The untransformed area of GA was measured by FAF. Baseline is defined as the last available, non-missing observation prior to first study drug administration.</description>
          <population>The mITT population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.</population>
          <units>mm^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="0.161"/>
                    <measurement group_id="O2" value="1.69" spread="0.168"/>
                    <measurement group_id="O3" value="2.12" spread="0.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score of the Study Eye at Month 12</title>
        <description>The BCVA letter score was determined using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. The score ranges from 0 to 100 letters, lower number indicating reduced visual acuity; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.</description>
        <time_frame>Baseline (Day 1) and Month 12.</time_frame>
        <population>The mITT population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Pegcetacoplan Monthly</title>
            <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Pegcetacoplan EOM</title>
            <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Sham Pooled</title>
            <description>Sham Monthly: Subjects received sham injections once monthly for 12 months.&#xD;
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score of the Study Eye at Month 12</title>
          <description>The BCVA letter score was determined using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. The score ranges from 0 to 100 letters, lower number indicating reduced visual acuity; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.</description>
          <population>The mITT population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.</population>
          <units>ETDRS letter score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.31" spread="1.352"/>
                    <measurement group_id="O2" value="-5.78" spread="1.398"/>
                    <measurement group_id="O3" value="-4.36" spread="1.364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Change From Baseline in Low Luminance BCVA (LL-BCVA) Score in the Study Eye at Month 12</title>
        <description>The LL-BCVA was measured by placing a 2.0-log-unit neutral density filter over the best correction and having the participant read the normally illuminated ETDRS chart. The score ranges from 0 to 100 letters, lower number indicating worse vision; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.</description>
        <time_frame>Baseline (Day 1) and Month 12.</time_frame>
        <population>The mITT population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Pegcetacoplan Monthly</title>
            <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Pegcetacoplan EOM</title>
            <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Sham Pooled</title>
            <description>Sham Monthly: Subjects received sham injections once monthly for 12 months.&#xD;
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Change From Baseline in Low Luminance BCVA (LL-BCVA) Score in the Study Eye at Month 12</title>
          <description>The LL-BCVA was measured by placing a 2.0-log-unit neutral density filter over the best correction and having the participant read the normally illuminated ETDRS chart. The score ranges from 0 to 100 letters, lower number indicating worse vision; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.</description>
          <population>The mITT population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.</population>
          <units>ETDRS letter score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.73" spread="1.145"/>
                    <measurement group_id="O2" value="-3.21" spread="1.184"/>
                    <measurement group_id="O3" value="-0.55" spread="1.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Change From Baseline in Low Luminance VA (LL-VA) Deficit Score in the Study Eye at Month 12</title>
        <description>The LL-VA deficit score is calculated as BCVA score minus LL-BCVA score. The LL-VA deficit score ranges from 0 to 100 letters, lower number indicating worse deficit.</description>
        <time_frame>Baseline (Day 1) and Month 12.</time_frame>
        <population>The mITT population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Pegcetacoplan Monthly</title>
            <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Pegcetacoplan EOM</title>
            <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Sham Pooled</title>
            <description>Sham Monthly: Subjects received sham injections once monthly for 12 months.&#xD;
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Change From Baseline in Low Luminance VA (LL-VA) Deficit Score in the Study Eye at Month 12</title>
          <description>The LL-VA deficit score is calculated as BCVA score minus LL-BCVA score. The LL-VA deficit score ranges from 0 to 100 letters, lower number indicating worse deficit.</description>
          <population>The mITT population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.</population>
          <units>ETDRS letter score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="1.382"/>
                    <measurement group_id="O2" value="-2.40" spread="1.424"/>
                    <measurement group_id="O3" value="-3.72" spread="1.385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Change From Baseline in Distance of GA Lesion From the Fovea (Foveal Encroachment) in the Study Eye at Month 12</title>
        <description>The foveal encroachment in the study eye was measured by FAF. Baseline is defined as the last available, non-missing observation prior to first study drug administration.</description>
        <time_frame>Baseline (Day 1) and Month 12.</time_frame>
        <population>The mITT population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Pegcetacoplan Monthly</title>
            <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Pegcetacoplan EOM</title>
            <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Sham Pooled</title>
            <description>Sham Monthly: Subjects received sham injections once monthly for 12 months.&#xD;
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Change From Baseline in Distance of GA Lesion From the Fovea (Foveal Encroachment) in the Study Eye at Month 12</title>
          <description>The foveal encroachment in the study eye was measured by FAF. Baseline is defined as the last available, non-missing observation prior to first study drug administration.</description>
          <population>The mITT population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.011"/>
                    <measurement group_id="O2" value="-0.04" spread="0.012"/>
                    <measurement group_id="O3" value="-0.06" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Macular Neovascularization (MNV) TEAEs in the Study Eye</title>
        <description>The number of subjects with any MNV TEAEs in the study eye was identified via clinical review of all ocular TEAEs.</description>
        <time_frame>From the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).</time_frame>
        <population>The safety population included all randomized subjects who received at least one injection of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Pegcetacoplan Monthly</title>
            <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Pegcetacoplan EOM</title>
            <description>Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Sham Pooled</title>
            <description>Sham Monthly: Subjects received sham injections once monthly for 12 months.&#xD;
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Macular Neovascularization (MNV) TEAEs in the Study Eye</title>
          <description>The number of subjects with any MNV TEAEs in the study eye was identified via clinical review of all ocular TEAEs.</description>
          <population>The safety population included all randomized subjects who received at least one injection of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).</time_frame>
      <desc>The safety population included all randomized subjects who received at least one injection of study drug.&#xD;
Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pegcetacoplan Monthly: Ocular Study Eye</title>
          <description>Ocular TEAEs are summarized for the study eye for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.</description>
        </group>
        <group group_id="E2">
          <title>Pegcetacoplan EOM: Ocular Study Eye</title>
          <description>Ocular TEAEs are summarized for the study eye for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.</description>
        </group>
        <group group_id="E3">
          <title>Sham Pooled: Ocular Study Eye</title>
          <description>Ocular TEAEs are summarized for the study eye for all subjects who randomized to sham monthly and sham EOM treatment groups.&#xD;
Sham Monthly: Subjects received sham injections once monthly for 12 months.&#xD;
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.</description>
        </group>
        <group group_id="E4">
          <title>Pegcetacoplan Monthly: Ocular Fellow Eye</title>
          <description>Ocular TEAEs are summarized for the fellow eye for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.</description>
        </group>
        <group group_id="E5">
          <title>Pegcetacoplan EOM: Ocular Fellow Eye</title>
          <description>Ocular TEAEs are summarized for the fellow eye for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.</description>
        </group>
        <group group_id="E6">
          <title>Sham Pooled: Ocular Fellow Eye</title>
          <description>Ocular TEAEs are summarized for the fellow eye for all subjects who randomized to sham monthly and sham EOM treatment groups.&#xD;
Sham Monthly: Subjects received sham injections once monthly for 12 months.&#xD;
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.</description>
        </group>
        <group group_id="E7">
          <title>Pegcetacoplan Monthly: Non-ocular</title>
          <description>Non-ocular (systemic) TEAEs are summarized for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.</description>
        </group>
        <group group_id="E8">
          <title>Pegcetacoplan EOM: Non-ocular</title>
          <description>Non-ocular (systemic) TEAEs are summarized for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.</description>
        </group>
        <group group_id="E9">
          <title>Sham Pooled: Non-ocular</title>
          <description>Non-ocular (systemic) TEAEs are summarized for all subjects who randomized to sham monthly and sham EOM treatment groups.&#xD;
Sham Monthly: Subjects received sham injections once monthly for 12 months.&#xD;
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="23" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Mitral valve calcification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Supraventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dry age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Oesophageal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Epidural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Spinal claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device extrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder outlet obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="23" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Apellis Clinical Trial Information Line</name_or_title>
      <organization>Apellis Pharmaceuticals, Inc</organization>
      <phone>1-833-284-6361</phone>
      <email>clinicaltrials@apellis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

